Overview
Retinalamin is a low-molecular-weight polypeptide complex derived from retinal tissue, developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike the very short, single-sequence tripeptides that make up much of the wider Khavinson catalogue (e.g. Pinealon, Vesugen), Retinalamin is a standardised peptide fraction — a complex mixture of low-molecular-weight polypeptides extracted from retinal tissue — rather than one fixed short amino acid sequence.
Retinalamin occupies a different position in this research family compared to most of the other bioregulators covered on this site. It has a more substantial documented clinical history in Russian ophthalmology and has been registered and used in Russian clinical practice as an adjunct treatment in a number of retinal disease contexts, including age-related macular degeneration (AMD), retinitis pigmentosa, diabetic retinopathy, and other retinal dystrophies. In Russian ophthalmology settings it has typically been administered via retrobulbar or subconjunctival injection, usually alongside standard-of-care management rather than as a replacement for it.
That said, this history should be read in proportion. Retinalamin is not approved or registered as a medicine in Ireland, the EU, or the UK, and it holds no marketing authorisation from the HPRA, EMA, or MHRA. The bulk of its supporting evidence comes from Russian-language clinical and preclinical literature, and while it has a longer real-world clinical track record than most Khavinson-class bioregulators, it has not been subjected to the scale or rigour of Western multi-centre randomised controlled trials that underpin approved Western ophthalmological pharmaceuticals. This guide summarises that research literature for educational and research purposes only — it is not a treatment recommendation, and nothing here should be read as suggesting Retinalamin is an approved or accessible therapy in Ireland.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human Clinical Studies (Russian, ophthalmology) |
✔ (moderate — registered clinical use in Russia) |
| Historical Regulatory Registration (Russia) |
✔ (ophthalmological adjunct indications) |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval (Ireland/EU/UK) |
✗ |
Mechanism of Action
Retinalamin's proposed mechanism follows the same general "tissue-specific bioregulator" framework used across Khavinson's research programme: peptide fractions derived from a given tissue are theorised to support the function of that same tissue type, on the premise that ageing and disease processes are linked to a decline in tissue-specific regulatory peptide signalling. In Retinalamin's case, the source tissue is retinal, and the peptide complex is proposed to act on retinal cell metabolism rather than through a single defined receptor-ligand interaction of the kind used to describe conventional ophthalmological drugs.
Russian research literature describes Retinalamin as having reported antioxidant, membrane-stabilising, and metabolism-supporting actions in retinal tissue, with proposed downstream effects on photoreceptor and retinal pigment epithelium function under conditions of oxidative and ischaemic stress. It has also been described in the literature as having a reported immunomodulatory action locally within ocular tissue. As with other bioregulator-class peptides, this mechanistic picture is substantially less defined than that of approved Western ophthalmological pharmaceuticals, and has not been independently replicated to the same standard outside the originating Russian research and clinical network.
Research Areas & Reported Effects
Age-Related Macular Degeneration (AMD)
Retinalamin has been studied as an adjunct in Russian clinical ophthalmology for dry and early exudative AMD, with reported outcomes describing has been observed to support in visual acuity and retinal function test markers (e.g. electroretinography parameters) when added to standard management. It is not presented in this literature as a replacement for anti-VEGF therapy or other standard AMD care.
Diabetic Retinopathy
Russian clinical studies describe Retinalamin used as a supportive adjunct in non-proliferative and early diabetic retinopathy, with reported findings relating to retinal microcirculation markers and electrophysiological retinal function tests alongside standard diabetic eye care.
Retinitis Pigmentosa and Retinal Dystrophies
A recurring research theme in the Russian ophthalmology literature is the use of Retinalamin in retinitis pigmentosa and other hereditary retinal dystrophies, where reported outcomes describe stabilisation of visual field and retinal function parameters over treatment courses, framed as supportive management rather than a disease-modifying cure.
Preclinical Retinal Protection Models
Animal and in vitro studies from the same research network report protective effects of the Retinalamin peptide fraction on retinal tissue exposed to oxidative and ischaemic stress, consistent with the antioxidant and membrane-stabilising mechanism proposed for the compound.
Research Data Summary
| Study / Model |
Reported Effect |
| Russian Clinical Cohort — AMD (adjunct use) |
Reported has been observed to support in visual acuity and electroretinography markers versus standard care alone. |
| Russian Clinical Cohort — Diabetic Retinopathy |
Reported has been observed to support in retinal microcirculation and functional test parameters. |
| Russian Clinical Cohort — Retinitis Pigmentosa |
Reported stabilisation of visual field and retinal function parameters over treatment courses. |
| Preclinical Ischaemia/Oxidative Stress Model |
Reported reduction in retinal tissue oxidative damage markers and membrane protection effects. |
Stack Combinations Studied
- Retinalamin + Cortexin → Research rationale: Both are Khavinson-network bioregulator peptide complexes studied together in Russian neuro-ophthalmology research contexts involving optic nerve and retinal-CNS interface conditions.
- Retinalamin + standard-of-care ophthalmological therapy → Research rationale: Studied predominantly as an adjunct alongside conventional AMD, diabetic retinopathy, and retinal dystrophy management in Russian clinical practice, not as a monotherapy.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Russian Clinical Ophthalmology Protocol |
Reported as retrobulbar or subconjunctival injection, dose per study protocol |
10-day course, typically repeated periodically |
Once daily during course |
Reported in Russian clinical use for AMD, diabetic retinopathy and retinal dystrophy as an adjunct to standard care. |
| Preclinical Retinal Protection Protocol |
Model-dependent, mcg range reported in Russian preclinical literature |
Study-dependent, days to weeks |
As per study protocol |
Oxidative and ischaemic retinal stress models in animal and in vitro research. |
Observed Side Effects in Research
- Russian clinical literature reports generally good local tolerability with retrobulbar/subconjunctival administration; localised injection-site discomfort has been reported
- Independent Western safety and toxicology data is not available
- Long-term safety data outside Russian clinical research and practice settings does not exist
- As an injection into or around the eye, any real-world use carries administration-related risks that are procedure-dependent and not something this page evaluates
Because independent Western clinical trial and toxicology data have not been generated, the tolerability profile described in Russian clinical literature should not be read as an internationally validated safety profile.
Compound Data
- CAS Number
- Not consistently assigned — Retinalamin is a standardised polypeptide complex/fraction rather than a single fixed-sequence compound
- Molecular Formula
- Not applicable — composed of a mixture of low-molecular-weight polypeptides extracted from retinal tissue, not one fixed molecular structure
- Molecular Weight
- Reported low-molecular-weight peptide fraction, generally under 10 kDa per component peptide (complex mixture, not a single value)
- Half-Life
- Not established in independently published Western pharmacokinetic literature
- Synonyms
- Retinal polypeptide complex, retinal tissue bioregulator, Khavinson-class ophthalmic peptide bioregulator
- Research Classification
- Khavinson-class polypeptide bioregulator complex, tissue-specific (retinal) research and clinical-use compound
Scientific References
The references below are drawn from Russian ophthalmology and gerontology research associated with Vladimir Khavinson's peptide bioregulator programme. Readers should note this evidence base, while including real registered clinical use and clinical studies in Russia, is still concentrated in Russian-language and Russian-affiliated journals and has not been replicated at the scale of Western multi-centre RCTs used to approve mainstream ophthalmological pharmaceuticals in the EU, UK or Ireland.
- [Khavinson VK, Trofimova SV et al.] — Retinalamin in the complex treatment of retinal dystrophies — Vestnik Oftalmologii (Russian Annals of Ophthalmology) — [Russian clinical research]
- [Trofimova SV, Khavinson VK] — Peptide bioregulators in ophthalmology: clinical experience with retinal tissue-derived polypeptides — Advances in Gerontology — [Russian clinical / review]
- [Khavinson VK et al.] — Antioxidant and membrane-protective effects of retinal polypeptide complexes in experimental models — Bulletin of Experimental Biology and Medicine — [Preclinical]
- [Trofimova SV et al.] — Clinical use of Retinalamin in diabetic retinopathy and age-related macular degeneration — Russian ophthalmology clinical literature — [Human, Russian clinical cohort]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*